IGF-1 Clinical Testing: A Comprehensive Technical Guide

Insulin-like Growth Factor 1 (IGF-1) clinical testing is a cornerstone laboratory tool for evaluating growth hormone (GH) related disorders, including acromegaly, gigantism, and growth hormone deficiency. Because IGF-1 reflects integrated GH secretion and remains stable throughout the day, it serves as a reliable first-line biomarker in endocrine diagnostics. This guide covers the technical principles, sample requirements, analytical methods, and clinical applications of IGF-1 clinical testing.

Technical Overview

Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a single-chain polypeptide composed of 70 amino acids with a molecular weight of approximately 7.6 kDa. It shares significant structural homology with proinsulin and is produced predominantly by hepatocytes under the stimulatory control of growth hormone through the JAK-STAT signaling pathway. IGF-1 mediates most of the anabolic and growth-promoting effects of GH, stimulating chondrocyte proliferation, protein synthesis, and tissue growth throughout the body.

Unlike GH, which is secreted in a pulsatile manner with a short plasma half-life of approximately 20 minutes, IGF-1 circulates with a half-life of 12 to 16 hours and provides a stable, integrated reflection of GH secretion over the preceding 24 to 48 hours. This physiological stability makes IGF-1 a superior screening biomarker for GH-related disorders compared to random GH measurement.

In circulation, more than 99% of IGF-1 is bound to six specific insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), with IGFBP-3 being the most abundant carrier. The majority of IGF-1 exists as a 150 kDa ternary complex consisting of IGF-1, IGFBP-3, and the acid-labile subunit (ALS). Serum IGF-1 concentrations are strongly age-dependent, rising from low levels in early childhood to peak values during puberty, then declining progressively with age. Consequently, accurate interpretation of clinical results requires age- and sex-specific reference intervals.

Testing Samples

Serum

Serum is the preferred specimen type for IGF-1 clinical testing. Venous blood should be collected into a standard serum separator tube (SST) or plain tube, typically requiring 2 to 5 mL of whole blood. After collection, the sample should be allowed to clot completely at room temperature for 30 minutes and centrifuged within 2 hours of collection to separate the serum from the clot.

Plasma

Plasma collected in EDTA or heparin anticoagulant tubes may be acceptable for certain automated assay platforms. However, assay-specific sample matrix requirements should always be verified in the manufacturer's instructions, as anticoagulants may interfere with some immunoassay systems.

Sample Handling and Stability

• Fasting collection is recommended but not strictly mandatory, as IGF-1 levels are less affected by acute nutritional intake than GH levels.
• Time of day is not critical because IGF-1 lacks significant diurnal variation.
• Serum samples remain stable at 2 to 8°C for up to 72 hours.
• For longer storage, samples should be frozen at -20°C or preferably -70°C.
• Repeated freeze-thaw cycles should be avoided, as they may degrade analyte integrity.
• Grossly hemolyzed, lipemic, or icteric samples should be rejected due to potential assay interference.

Testing Items

The primary testing item is the quantitative measurement of serum IGF-1 concentration, reported in ng/mL or nmol/L (conversion factor: 1 ng/mL × 0.130 = 1 nmol/L). Results should be interpreted against age- and sex-matched reference intervals, ideally expressed as standard deviation scores (Z-scores) or percentiles derived from a validated normative database.

• IGF-1 concentration: the core analyte for evaluating GH axis function.
• IGFBP-3: frequently measured alongside IGF-1 as an adjunct marker, particularly in pediatric growth disorder evaluations, given its co-regulation with GH and longer half-life.
• IGF-1 Z-score: a normalized value indicating how far a patient's result deviates from the age- and sex-adjusted mean, facilitating clinical classification.

Testing Methods

Several analytical platforms are available for IGF-1 quantification, each with distinct technical characteristics that influence result accuracy and comparability.

Immunoassays

Automated immunoassays represent the most widely used methodology in routine clinical laboratories. Chemiluminescent immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) platforms employ sandwich-format detection using capture and detection antibodies directed against IGF-1. A critical pre-analytical step in these assays is the dissociation of IGF-1 from its binding proteins, typically achieved through acidification or acid-ethanol extraction. Incomplete release of IGF-1 from IGFBPs is a major source of analytical interference and can lead to falsely elevated or reduced results.

Immunoradiometric Assay (IRMA)

Historically considered a reference immunoassay format, IRMA offers high sensitivity and specificity but has declined in popularity due to radioactive waste handling requirements and limited automation capability.

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

LC-MS/MS is increasingly recognized as the preferred methodology for IGF-1 measurement due to its high analytical specificity, wide linear dynamic range, and freedom from antibody-related cross-reactivity. Unlike immunoassays, LC-MS/MS directly quantifies intact IGF-1 molecules, eliminating interference from binding proteins and heterophilic antibodies. This method facilitates harmonization of results across laboratories and is recommended by current consensus guidelines for acromegaly management.

Quality Considerations

• Substantial inter-method variability exists between different IGF-1 immunoassays, with discrepancies of up to 30% reported between platforms.
• Laboratories must establish or adopt assay-specific, age- and sex-stratified reference intervals validated for their local population.
• Participation in external quality assessment (EQA) or proficiency testing programs is essential for monitoring analytical performance.
• Serial monitoring of individual patients should ideally be performed using the same assay platform to ensure result comparability.

Applications

Diagnosis of Growth Hormone Excess

Elevated serum IGF-1, adjusted for age and sex, is a key diagnostic criterion for acromegaly and gigantism. According to international consensus guidelines, a random IGF-1 level above the age-adjusted reference range in a patient with compatible clinical features strongly supports the diagnosis, and IGF-1 measurement is recommended as the initial biochemical test.

Diagnosis of Growth Hormone Deficiency

In children with short stature and in adults with suspected pituitary dysfunction, a low IGF-1 level provides supportive evidence for GH deficiency. While IGF-1 alone cannot definitively exclude the diagnosis due to overlap with normal ranges, markedly reduced values increase diagnostic probability and guide the need for provocative GH stimulation testing.

Monitoring of Therapy

• Assessment of recombinant human GH (rhGH) replacement therapy adequacy, with dose titration targeting IGF-1 levels within the mid-normal reference range.
• Post-operative surveillance of acromegaly patients, where persistent IGF-1 elevation indicates biochemical remission failure or disease recurrence.
• Monitoring of medical therapy with somatostatin analogs, GH receptor antagonists, or dopamine agonists in acromegaly.

Pediatric Growth Evaluation

IGF-1 measurement, often combined with IGFBP-3, forms part of the systematic diagnostic workup for growth retardation, helping to differentiate GH-related causes from constitutional delay, genetic short stature, or systemic disease.

Additional Clinical and Research Uses

• Nutritional status assessment, as IGF-1 is highly sensitive to protein-calorie intake and hepatic synthetic function.
• Evaluation of chronic liver disease severity.
• Investigation of hypothyroidism and other endocrine conditions affecting the GH-IGF axis.

FAQ

Why is IGF-1 measured instead of growth hormone for screening?

Growth hormone is secreted in pulsatile bursts with dramatic minute-to-minute fluctuations, making a single random GH measurement unreliable for diagnosis. IGF-1 has a long half-life, minimal diurnal variation, and integrates total GH secretion, providing a far more stable and clinically interpretable result from a single blood draw.

Is fasting required before IGF-1 testing?

Fasting is recommended but not strictly required. IGF-1 levels are considerably less sensitive to acute food intake than GH levels. However, a morning fasting sample is preferred to standardize conditions and eliminate any potential minor nutritional influence, particularly when GH is measured concurrently.

What does an elevated IGF-1 level indicate?

An age-adjusted elevation of IGF-1 most commonly suggests GH excess, as seen in acromegaly (adults) or gigantism (children). Physiological causes of elevation include puberty and pregnancy. Mild increases may also occur with high-protein diets or hyperthyroidism. Confirmatory testing, including GH measurement during oral glucose tolerance testing and pituitary imaging, is typically required.

What does a low IGF-1 level indicate?

Reduced IGF-1 may indicate growth hormone deficiency, malnutrition or prolonged fasting, chronic liver disease, hypothyroidism, poorly controlled diabetes, or acute critical illness. In children, low levels warrant further evaluation with GH stimulation tests. It should be noted that a normal IGF-1 result does not exclude GH deficiency in all cases.

Do IGF-1 reference ranges change with age?

Yes. IGF-1 concentrations are lowest in infancy and old age, peak during pubertal development between ages 13 and 17, and decline steadily thereafter. Every laboratory report must be interpreted using age- and sex-specific reference intervals; using a single adult range for all patients leads to significant diagnostic errors.

Why is IGFBP-3 sometimes measured together with IGF-1?

IGFBP-3 is the principal carrier protein for IGF-1 and is co-regulated by GH. In pediatric evaluations, combining IGFBP-3 with IGF-1 improves diagnostic sensitivity for GH deficiency, since IGFBP-3 exhibits minimal nutritional dependence and a long half-life, providing complementary information about GH axis status.